David K. Chiu
Hong Kong Island
Hong Kong, HCW, Hong Kong Special Administrative Region
Hong Kong, HCW, Hong Kong Special Administrative Region
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Pharmacologic glycoengineering of Fcγ receptor IIIa enhances force-resistant IgG-FcγR interactions and anti-tumor antibody efficacy.
Journal: Immunity
Published: October 21, 2025
Hijacking erythropoietin: A tumour-intrinsic strategy to escape immune surveillance.
Journal: Clinical and translational medicine
Published: July 09, 2025
Tumor-derived erythropoietin acts as an immunosuppressive switch in cancer immunity.
Journal: Science (New York, N.Y.)
Published: April 24, 2025
The acid-sensing receptor GPR65 on tumor macrophages drives tumor growth in obesity.
Journal: Science immunology
Published: October 18, 2024
Sialylated IgG induces the transcription factor REST in alveolar macrophages to protect against lung inflammation and severe influenza disease.
Journal: Immunity
Published: June 15, 2024
Hypoxia-inducible factor orchestrates adenosine metabolism to promote liver cancer development.
Journal: Science advances
Published: May 05, 2023
Matrix viscoelasticity promotes liver cancer progression in the pre-cirrhotic liver.
Journal: Nature
Published: September 21, 2022
CFI-402257, a TTK inhibitor, effectively suppresses hepatocellular carcinoma.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: August 01, 2022
Neutrophil-activating therapy for the treatment of cancer.
Journal: Cancer cell
Published: December 01, 2021
Polo-like kinase 4 inhibitor CFI-400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity.
Journal: Hepatology (Baltimore, Md.)
Published: August 30, 2021
Last Updated: 09/26/2026